NEW YORK (GenomeWeb) – PerkinElmer said today that it has completed the acquisition of Swedish firm Vanadis Diagnostics.
Vanadis is developing a non-invasive prenatal testing solution based on digital analysis of cell-free DNA for use in biochemistry and genetic laboratories. According to PerkinElmer, the Vanadis portfolio will expand its existing maternal fetal health offerings, which include prenatal, neonatal, and infectious disease screening. By combining both product sets, PerkinElmer will be able to offer simple, cost-effective high-throughput NIPT solutions for detecting fetal chromosomal abnormalities, the company said.
"While NIPT is becoming increasingly recognized as valuable to many high-risk expectant parents during the first trimester, test complexity and pricing issues have limited the ability of many biochemistry labs to effectively offer this type of prenatal screening," Prahlad Singh, PerkinElmer's president, diagnostics, said in a statement. "Vanadis' simplified NIPT platform ... should help overcome these obstacles, giving labs a wider range of prenatal testing capabilities and providing important information to physicians and patients."
Financial and other terms of the acquisition were not disclosed.